Here are five takeaways.
1. Stryker’s net sales increased 9.7 percent year-over-year, generating $3.2 billion in sales.
2. In its orthopedics segment, Stryker reported a 7.1 percent increase in sales year-over-year, with 4.7 percent being organic. Net sales totaled $1.2 billion for the quarter.
3. Within the medsurg segment, Stryker reported a 9.3 percent increase in sales year-over-year, with 7.8 percent being organic and 1.3 percent being through acquisitions. Net sales totaled $1.4 billion for the quarter.
4. Stryker’s neurotechnology and spine segment experience the largest growth, as expect. The company reported a 16.1 percent increase in sales year-over-year, with 3.4 percent through acquisitions and 10.1 percent organically. Net sales totaled $600 million for the quarter.
5. Based on it’s first quarter performance, Stryker expects its second quarter diluted earnings per share to be between $1.70 to $1.75.
More articles on devices and implants:
Jury sides with spine surgeon in case of off-label use of Medtronic’s Infuse: 6 things to know
Zimmer Biomet reports a 2.3% jump in sales, spine segment generates $183M: 5 Q1 details
CoreLink appoints David Castleman 1st VP of research and development: 5 things to note
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
